Language:

Hepatocellular carcinoma

The Lancet (British edition), 2022-10, Vol.400 (10360), p.1345-1362 [Peer Reviewed Journal]

2022. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(22)01200-4

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Hepatocellular carcinoma
Author: Vogel, Arndt ; Meyer, Tim ; Sapisochin, Gonzalo ; Salem, Riad ; Saborowski, Anna
Subjects: Abdomen ; Ablation ; Alcohol ; Biomarkers ; Biopsy ; Cancer ; Cancer therapies ; Coffee ; Decision making ; Diabetes ; Epidemiology ; Ethnicity ; Fatty liver ; Global health ; Health services ; Hepatitis ; Hepatitis B ; Hepatitis C ; Hepatocellular carcinoma ; Immune checkpoint inhibitors ; Immunization ; Immunosuppressive agents ; Liver ; Liver cancer ; Liver cirrhosis ; Liver diseases ; Liver transplantation ; Medical prognosis ; Metabolism ; Mortality ; Obesity ; Patients ; Public health ; Radiation ; Risk analysis ; Risk factors ; Surveillance ; Transplantation ; Tumors ; Ultrasonic imaging
Is Part Of: The Lancet (British edition), 2022-10, Vol.400 (10360), p.1345-1362
Description: Summary Hepatocellular carcinoma is one of the most common cancers worldwide and represents a major global health-care challenge. Although viral hepatitis and alcohol remain important risk factors, non-alcoholic fatty liver disease is rapidly becoming a dominant cause of hepatocellular carcinoma. A broad range of treatment options are available for patients with hepatocellular carcinoma, including liver transplantation, surgical resection, percutaneous ablation, and radiation, as well as transarterial and systemic therapies. As such, clinical decision making requires a multidisciplinary team that longitudinally adapts the individual treatment strategy according to the patient's tumour stage, liver function, and performance status. With the approval of new first-line agents and second-line agents, as well as the establishment of immune checkpoint inhibitor-based therapies as standard of care, the treatment landscape of advanced hepatocellular carcinoma is more diversified than ever. Consequently, the outlook for patients with hepatocellular carcinoma has improved. However, the optimal sequencing of drugs remains to be defined, and predictive biomarkers are urgently needed to inform treatment selection. In this Seminar, we present an update on the causes, diagnosis, molecular classification, and treatment of hepatocellular carcinoma.
Publisher: London: Elsevier Limited
Language: English
Identifier: ISSN: 0140-6736
EISSN: 1474-547X
DOI: 10.1016/S0140-6736(22)01200-4
Source: ProQuest One Psychology
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Hepatocellular carcinoma

2022. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(22)01200-4

Searching Remote Databases, Please Wait